Clinical Trial

Topical Diclofenac for Prevention of Radiation-induced Dermatitis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy. The main pathways of RID is inflammation and oxidative stress on local and systemic bases. The Diclofenac is a COX-2 inhibitor and Nonsteroidal anti-inflammatory drugs whose anti-inflammatory and antioxidant activities have been proven in several clinical trials. Thus, the aim of the present study is to evaluate the efficacy of Diclofenac sodium gel as a prophylactic method against the development of RID.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-25; most recent amendment 2026-03-30.
Trial Details
NCT Number NCT06905561
Lead Sponsor The Second Affiliated Hospital of Hainan Medical University
Conditions Head and Neck Tumor, Breast Cancer
Enrollment 156 participants
Start Date 2025-02-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-03